Viscient Biosciences
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11575 Sorrento Valley Rd Ste 208, San Di...Website
www.viscientbiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Viscient Biosciences
Viscient Biosciences is a biotechnology company that specializes in 3D tissue technology to revolutionize drug development. By utilizing human tissue models, they aim to replace outdated animal models, demonstrating significant advancements in understanding diseases such as fatty liver disease. The company has successfully developed one drug to the preclinical stage and is preparing for Phase 1 studies, while also in-licensing a second drug for Phase 2 studies in 2024. Their innovative approach is supported by leading academic research, showcasing the potential of their models in accurately reflecting disease patterns.Explore more
Viscient Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Viscient Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Viscient Biosciences is spiking on competitors!
Product Launch: Get notified when Viscient Biosciences launches new products
Funding: Get notified immidiatlly once Viscient Biosciences has new funding data
Viscient Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Viscient Biosciences
Click to see if Viscient Biosciences had a recent Job posting/layoffs
Earning: See what the market has to say on Viscient Biosciences recently announced quarterly report
Check if Viscient Biosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Viscient Biosciences
Compare insights from companies similar to Viscient Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Viscient Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Viscient Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Viscient Biosciences.
Viscient Biosciences Tech Stack
A closer look at the technologies used by Viscient Biosciences
Viscient Biosciences News & Media
Viscient Biosciences Announces First Drug Discovered in 3D Bioprinted Models
Company's NASH Drug Expected to Enter Clinic in 2024 SAN DIEGO, May 2, 2023 /PRNewswire/ -- Viscient Bio, Inc. ("Viscient") today announced it has identified the world's first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells....Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt
Keith Murphy, founder and Chief Executive Officer of Viscient Biosciences ("Viscient"), today is calling for a pause in the merger attempt of Organovo Holdings, Inc ("Organovo"), after Organovo failed to receive enough votes to consummate the merger. Mr. Murphy also founded Organovo, was its former CEO and Chairman Emeritus, and has opposed the merger as a 1% stockholder of Organovo. Given the conditions of global pandemic and the opportunity for 3D bioprinting technology to assistViscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential in Drug Discovery With Organovo
SAN DIEGO--(BUSINESS WIRE)--Viscient Biosciences (“Viscient”), a biotech therapeutics company working at the intersection of 3D tissue technology and transcriptomics technology to discover and develop drugs across a range of therapeutic areas with significant unmet medical need, today announced that it has formally submitted a merger proposal to Organovo Holdings, Inc.’s (“Organovo”) Board of Directors to combine the two companies. Viscient has previously made strides forward using 3D liver tis
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Viscient Biosciences
Sign Up For FreeTo access detailed company insights
Viscient Biosciences is a biotechnology company that specializes in 3D tissue technology to revolutionize drug development. By utilizing human tissue models, they aim to replace outdated animal models, demonstrating significant advancements in understanding diseases such as fatty liver disease. The company has successfully developed one drug to the... Read More
